1. Home
  2. ACTG vs RLMD Comparison

ACTG vs RLMD Comparison

Compare ACTG & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acacia Research Corporation (Acacia Tech)

ACTG

Acacia Research Corporation (Acacia Tech)

N/A

Current Price

$4.36

Market Cap

440.1M

Sector

Miscellaneous

ML Signal

N/A

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

N/A

Current Price

$3.66

Market Cap

461.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACTG
RLMD
Founded
1993
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
440.1M
461.9M
IPO Year
1995
2012

Fundamental Metrics

Financial Performance
Metric
ACTG
RLMD
Price
$4.36
$3.66
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $10.75
AVG Volume (30 Days)
164.5K
★ 1.2M
Earning Date
11-04-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 161.11
45.28
EPS
★ N/A
N/A
Revenue
★ $12,004,000.00
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 154.83
52 Week Low
$3.22
$1.80
52 Week High
$5.27
$8.00

Technical Indicators

Market Signals
Indicator
ACTG
RLMD
Relative Strength Index (RSI) N/A 31.29
Support Level N/A $3.57
Resistance Level N/A $4.44
Average True Range (ATR) 0.00 0.19
MACD 0.00 -0.02
Stochastic Oscillator 0.00 4.38

Price Performance

Historical Comparison
ACTG
RLMD

About ACTG Acacia Research Corporation (Acacia Tech)

Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations, and Manufacturing Operations. It derives revenue from the Intellectual Property Operations segment. Geographically, it operates in the Americas, Europe, the Middle East and Africa, China, India, and Asia-Pacific.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: